Gilead Sciences (GILD) Potential M&A In Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
UBS Reiterates Buy on Alexion Pharma (ALXN) Following 4Q EPS Beat
February 4, 2016 8:39 AM ESTUBS maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $200.00 (from $222.00), following the company's 4Q earnings report. ALXN reported a $0.03 EPS beat, despite a $7m miss in Soliris sales, and a $4m miss in operating income, due to a beat on taxes and higher non-operating income.
Analyst... More
Gilead (GILD) Needs Impactful M&A for the Next Leg of Growth - Piper Jaffray
February 3, 2016 9:11 AM ESTPiper Jaffray analyst, Joshua Schimmer, is hoping to see an impactful acquisition to propel Gilead Sciences (NASDAQ: GILD) into its next leg of growth. However, at 7x next year's eps, the stock may have hit bottom.
GILD reported a very strong 4Q15, bolstered by strong HCV sales in Japan, partially offset by limited VA HCV starts in the quarter. The company guided to flat/slightly down product sales in 2016 and a significant uptick in R&D (+12%-23%) and SG&A (+2%-12%). The company is increasing its dividend... More
Gilead's (GILD) Increased Unit Sales Tempered By Lower Prices - Oppenheimer
February 3, 2016 7:11 AM ESTOppenheimer analyst, Wendy Lam, trimmed her price target on Gilead Sciences (NASDAQ: GILD) as the increasing volume of Harvoni will be offset by reductions in price. One bright note was the strong start to HIV as Genvoya generated $44B in sales. PT is cut to $120 from $124 but maintaining the Outperform rating.
GILD reported 4Q15 revenue of $8.5B and non-GAAP EPS of $3.32, topping Street consensus estimates of $8.2B and $3.00. However, GILD's 2016 guidance on net product sales of... More
